

Friday, March 24, 2023

8:00 - 8:15 am	INTRODUCTIO	N AND WELCOME
0.00 - 0.13 alli		IN AND WELCOME

CHAIRS: Nikhil Munshi, Adam Cohen, Hermann Einsele

CHAIRS: Sundar Jagannath and Philippe Moreau Update on ide-cel and cilta-cel in late-line MM Real world outcomes with CAR T cells for MM Update on other autologous CAR T cells Should we move CAR T cells to early relapse/front line	Noopur Raje Doris Hansen Matthew Frigault	
Real world outcomes with CAR T cells for MM Update on other autologous CAR T cells	Doris Hansen	
Update on other autologous CAR T cells		
	Matthew Frigault	
Should we move CAR T cells to early relanse/front line		
Should We move child realis to early relapsement line	Tom Martin	
Discussion	Session faculty + Surbhi Sidana	
CLINICAL UPDATES ON BISPECIFIC ABS	/TCE'S	
CHAIRS: Saad Usmani and Amrita Krishnan		
BCMA bsAbs part 1: Teclistamab and Elranatamab	Alexander Lesokhir	
BCMA bsAbs part 2: REGN5458, ABBV-383, HPN217, CC-93269	Hermann Einsele	
Talquetamab, Cevostamab and other non-BCMA bispecifics	Adam Cohen	
Treating relapse after bsAb and CART therapies	Samir Parekh	
Discussion	Session faculty + Philippe Moreau	
	CLINICAL UPDATES ON BISPECIFIC ABSACHAIRS: Saad Usmani and Amrita Krishnan BCMA bsAbs part 1: Teclistamab and Elranatamab BCMA bsAbs part 2: REGN5458, ABBV-383, HPN217, CC-93269 Talquetamab, Cevostamab and other non-BCMA bispecifics Treating relapse after bsAb and CART therapies	

11:30 am - 1:00 pm	REAL WORLD CONSIDERATIONS FOR T CELL DIRECTED THERAPIES			
	CHAIRS: Nikhil Munshi and Francesca Gay			
11:30-11:42	Managing logistics of commercial CART therapies	Yi Lin		
11:42-11:54	How should we sequence BCMA directed therapies Is there a role for maintenance therapy post-CART? Role of MRD testing after CAR T and bsAb therapy	Krina Patel Alfred Garfall Bruno Paiva		
11:54-12:06				
12:06-12:18 12:18-1:00				
	Discussion	Session faculty + Nikhil Munshi, Hermann Einsele		
1:00 - 1:45 pm	LUNCH			
1:45 - 3:15 pm	NEXT GENERATION CELL THERAPY APPROACHES			
	CHAIRS: Kenneth Anderson and Maria-Victoria Mateos			
1:45-1:57	Novel CART manufacturing approaches	Adam Sperling		
1:57-2:09	Allogeneic CAR T approaches NK-based CAR and bispecific approaches	Sham Mailankody		
2:09-2:21		Jeffrey Miller		
2:21-2:33	CAR-macrophage therapy for cancer	Michael Hudecek		
2:33-3:15	Discussion	Session faculty + Salomon Manier		
3:15 - 3:30 pm	BREAK			
3:30 - 4:50 pm	MANAGING TOXICITIES OF T CELL DIRECTED THERAPIES			
	CHAIRS: Jesus Berdeja and Ajai Chari			
3:30-3:42	COVID vaccine responses post-BCMA directed treatments	Evangelos Terpos		
3:42-3:54	Strategies to mitigate risk of CRS and HLH	Sandy Wong		
3:54-4:06	What's new in prevention and management of neurotoxicity?	Bianca Santomasso		
4:06-4:50	Discussion	Session faculty + Omar Nadeem		

Saturday, March 25, 2023

8:00 - 8:05 am	WELCOME	
8:05 - 8:35 am	PLENARY TALK: MICROBIOME	Marcel van den Brink

8:35 - 10:10 am	DETERMINANTS OF RESPONSE/RESISTANCE PART I			
	CHAIRS: Carlos Fernandez de Larrea and David Avigan			
8:35-8:47	Overview of resistance mechanisms	Niels van de Donk		
8:47-8:59	Predicting response to CAR T cells: lessons from CD19 CARTs	Mark Leick Mehmet Samur Enrique Zudaire		
8:59-9:11	Correlates of ide-cel response			
9:11-9:23	Correlates of cilta cel response			
9:23-10:10	Discussion	Session faculty + Paola Neri		
10:10 - 10:30 am	BREAK			
10:30 am - 12:00 pm	DETERMINANTS OF RESPONSE/RESISTANCE PART II			
	CHAIRS: Joaquin Martinez-Lopez and Maria Themeli			
10:30-10:42	Profiling immune cells in BsAb therapy	Nizar Bahlis		
10:42-10:54	Role of antigen loss in resistance	Leo Rasche		
10:54-11:06	Role of microenvironment in response/resistance	Madhav Dhodapkar		
11:06-11:18	Impact of diet and microbiome on immunotheraphy for myeloma	Matteo Bellone		
11:18-12:00	Discussion	Session faculty + Adam Cohen		
12:00 - 12:45 pm	LUNCH			
12:45 - 2:15 pm	OVERCOMING RESISTANCE TO T CELL-DIRECTED THERAPIES			
	CHAIRS: Kwee Yong and Pieter Sonneveld			
12:45-12:57	Dual-targeted CAR T cells	Eric Smith		
12:57-1:09	Identifying novel surface Ag targets	Arun Wiita		
1:09-1:21	Enhancing responses to T cell directed therapies	Michael Hudecek		
1:21-1:33	Targeting fibroblasts to improve T cell therapy	Saad Kenderian		
1:33-1:45	Gamma secretase inhibition	Damian Green		
1:45-2:15	Discussion	Session faculty + Ivan Borrello		
2:15 - 3:00 pm	WORKSHOP ON INFECTION PREVENTION			
	CHAIRS: Nikhil Munshi and Hermann Einsele			
2:15-2:30	Optimizing infection prevention post-CAR T and BsAb therapy	Sarah Hammond		
2:30-3:00	Discussion	Session faculty + Noopur Raje, Marc Raab		
3:00 - 3:15 pm	WRAP UP			

Thank you to our sponsors

TITANIUM

Bristol Myers Squibb™



PLATINUM



SILVER



